MAPS PBC announces positive topline results from long-term observational follow-up study on MDMA-assisted therapy for treatment of PTSD.

Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session.

Findings are consistent with previously published Phase 2 data[1] on the sustained effect of MDMA-assisted therapy for the treatment of PTSD.